CIPLA

Cipla – Negative; Partner Unit Gets Import Alert Cipla’s partner unit - Pharmathen's Rodopi - as per FDA's website is under import alert Cipla has partnership with Pharmathen International S.A. - specifically its Rodopi, Greece facility This unit manufactures Lanreotide Injection This means Lanreotide Injection revenue goes out of estimates Analyst expected $50-60 million revenue in FY27 and $100 million in FY28 from Lanreotide Injection